Marco Chiadò Piat, President, Pharmaceutical Solutions Division, Terumo Medical Solutions, outlined a $500-million expansion plan, which includes an acquisition and organic growth, at the DCAT Member Company Announcement Forum, held March 23, 2026, at DCAT Week.

The company has CDMO expertise across three manufacturing sites in Japan, and in 2025, acquired a drug-product plant and associated quality control laboratory operations in Leverkusen, Germany. The acquisition provides Terumo capabilities for fill–finish services for vials and polymer prefillable syringes, including device assembly. The move enables the company to meet growing demand for CDMO services, particularly in Europe and the United States.

Following the EUR 150-million ($175-million)-acquisition, integration is expected to be completed by October 2026. The company is investing an additional $50 million to expand the recently acquired site in Germany. The acquisition also broadens the company’s product and service portfolio, adding competencies in prefillable polymer syringes, fill–finish, device assembly, auto-injectors and safety devices, and component assembly, such as plunger rods and finger grips, alongside downstream operations such as labeling, printing and blistering.

In addition, the company is allocating an additional $350 million to further advance its CDMO capabilities in Japan to bring its total investment in its global CDMO growth plan to over $500 million.